Insulin resistance and cardiovascular disease
Open accessThe DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
Abstract
Insulin resistance (IR) and cardiovascular disease (CVD) represent two universal public health hazards, especially in today’s Western societies. A causal-effect relationship has been established that links IR with CVD. The mediating mechanisms are perplexing, under ongoing, rigorous investigation and remain to be fully elucidated. IR is a condition encompassing hyperglycemia and compensatory hyperinsulinemia. It occurs when insulin is not capable of exerting its maximum effects on target tissues, including skeletal muscles, liver and adipose tissue. This alteration of insulin signaling pathways results in the development of cardiometabolic disorders, including obesity, dyslipidemia, low-grade inflammation, endothelial dysfunction and hypertension, all of which are predisposing factors for atherosclerosis and CVD. The management of IR can be achieved through dietary modifications, the inclusion of regular exercise routines in everyday life, pharmacological agents and other interventions tailored to each individual patient’s needs. It is important to underline though that, although various antidiabetic drugs that may improve IR are available, no medications are as yet specifically approved for the treatment of IR. This narrative review will focus on the current scientific and clinical evidence pertaining to IR, the mechanisms connecting IR with CVD, as well as plausible strategies for a holistic, personalized approach for IR management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–268 of 268
Zheng, S., Chen, N., Kang, X.-J., Hu, Y., & Shi, S. (2021) · Endocrine · doi:10.1007/s12020-021-02875-y · Cited by 80
Kosmas, C. E., Silverio, D., Tsomidou, C., Salcedo, M. D., Montan, P. D., & Guzman, E. (2018) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551418792257 · Cited by 77
Self-citationTettamanzi, F., Bagnardi, V., Louca, P., Nogal, A., Monti, G. S., Mambrini, S. P., Lucchetti, E., Maestrini, S., Mazza, S., Rodriguez-Mateos, A., et al. (2021) · Nutrients · doi:10.3390/nu13124380 · Cited by 77
Nyström, T. (2008) · Hormone and Metabolic Research · doi:10.1055/s-0028-1082326 · Cited by 76
Oxidative mechanisms and atherothrombotic cardiovascular disease
Leopold, J. A., & Loscalzo, J. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.02.001 · Cited by 75
Sartori, C. S., & Scherrer, U. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917110-00003 · Cited by 74
Insulin Resistance, Polycystic Ovary Syndrome and Metformin
PUGEAT, M. M., & Ducluzeau, P. (1999) · Drugs · doi:10.2165/00003495-199958001-00010 · Cited by 72
High-Intensity Functional Training: Molecular Mechanisms and Benefits
Ben-Zeev, T., & Okun, E. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08638-8 · Cited by 72
Clinical implications of fetuin-A
Jirak, P., Stechemesser, L., Morè, E., Franzen, M., Topf, A., Mirna, M., Paar, V., Pistulli, R., Kretzschmar, D., Wernly, B., et al. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.12.003 · Cited by 69
Villarreal-Calderón, J. R., Cuellar-Támez, R. X., Ramos-González, M. R., Rubio‐Infante, N., Castillo, E. C., Elizondo‐Montemayor, L., & García‐Rivas, G. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3940739 · Cited by 69
Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors
Howes, L. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3784 · Cited by 67
Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis
Guo, V. Y., Cao, B., Cai, C. C., Cheng, K. K. Y., & Cheung, B. M. Y. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1068-9 · Cited by 67
Willems, A. E. M., Sura–de Jong, M., van Beek, A. P., Nederhof, E., & van Dijk, G. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa044 · Cited by 66
Nutritional guidelines for the management of insulin resistance
Muscogiuri, G., Barrea, L., Caprio, M., Ceriani, F., Chavez, A. O., El Ghoch, M., Frias-Toral, E., Mehta, R. J., Mendez, V., Paschou, S. A., et al. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1908223 · Cited by 63 · cited 1×
“Undoubtedly, clinicians ought to personalize and tailor dietary and exercise plans to each patient’s metabolic profile, preferences, habits and lifestyle for maximum efficacy.(168,169) 12 Journal of International Medical Research”
Backgroundvon Bibra, H., Saha, S., Hapfelmeier, A., Müller, G., & Schwarz, P. E. H. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-107782 · Cited by 63
Schmiegelow, M., Hedlin, H., Stefanick, M. L., Mackey, R. H., Allison, M., Martin, L. W., Robinson, J. G., & Hlatky, M. A. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001563 · Cited by 62
β-Cell preservation with thiazolidinediones
Campbell, I. W., & Mariz, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.08.015 · Cited by 61
The Chemistry and Biochemistry of Insulin
Klostermeyer, H., & HUMBEL, R. E. (1966) · Angewandte Chemie International Edition in English · doi:10.1002/anie.196608071 · Cited by 61
Insulin resistance and metformin in polycystic ovary syndrome
Ben‐Haroush, A., Yogev, Y., & Fisch, B. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2003.11.027 · Cited by 59
Adipose tissue expandability, lipotoxicity and the metabolic syndrome
Vidal‐Puig, A. (2013) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(13)70026-3 · Cited by 58
Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Katsiki, N., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206100750 · Cited by 57
Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials
He, L., Liu, X., Wang, L., & Yang, Z. (2016) · Medicine · doi:10.1097/md.0000000000004947 · Cited by 55
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 55
Song, R., Zhao, X., Cao, R. Y., Liang, Y., Zhang, D., & Wang, R. (2020) · Gene · doi:10.1016/j.gene.2020.145209 · Cited by 55
Insulin resistance in hypertension and cardiovascular disease
Lamounier‐Zepter, V., Ehrhart‐Bornstein, M., & Bornstein, S. R. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.002 · Cited by 52
Adropin regulates hepatic glucose production via PP2A/AMPK pathway in insulin‐resistant hepatocytes
Chen, X., Chen, S., Shen, T., Yang, W., Chen, Q., Zhang, P., You, Y., Sun, X., Xu, H., Tang, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000115rr · Cited by 51
Update on the synergistic effect of HSL and insulin in the treatment of metabolic disorders
Lan, Y., Lou, J., Lyu, W., & Zhang, B. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819877300 · Cited by 50
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Zhang, Y., Liu, X., Zhang, H., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836455 · Cited by 47
Li, Z., Lin, M., Liu, C., Wang, D., Shi, X., Zheng, C., Liu, Y., Yang, S., & Li, X. (2018) · Cytokine · doi:10.1016/j.cyto.2018.03.023 · Cited by 46
The role of miRNAs in polycystic ovary syndrome with insulin resistance
Luo, Y., Cui, C., Han, X., Wang, Q., & Zhang, C. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-02019-7 · Cited by 46
Insulin resistance, a new target for nitric oxide‐delivery drugs
Cook, S., & Scherrer, U. (2002) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00130.x · Cited by 44
Qu, H., Qiu, Y., Wang, Y., Liao, Y., Zheng, Y., & Zheng, H. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.003 · Cited by 43
Insulin resistance and hyperinsulinemia in hypertension
Weidmann, P. U., hlen, L. B., & de Courten, M. (1995) · Journal of Hypertension · doi:10.1097/00004872-199508001-00010 · Cited by 42
Role of the glucose‐sensing receptor in insulin secretion
Kojima, I., Medina, J., & Nakagawa, Y. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13013 · Cited by 42
Liu, S., Hu, W., He, Y., Li, L., Liu, H., Gao, L., Yang, G., & Liao, X. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0538-1 · Cited by 41
Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis
He, K., Li, J., Wang, X., Ge, J., Sun, J., & Jing, Z. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109791 · Cited by 41
Sinha, B., & Ghosal, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.830401 · Cited by 40
Punthakee, Z., Alméras, N., Després, J. ‐., Dagenais, G. R., Anand, S. S., Hunt, D. L., Sharma, A. M., Jung, H., Yusuf, S., & Gerstein, H. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12512 · Cited by 39
Wong, C., Dash, A., Fredrickson, J. O., Lewin‐Koh, N., Chen, S., Yoshida, K. J., Liu, Y., Gutierrez, J., & Kunder, R. S. (2022) · Hepatology · doi:10.1002/hep.32742 · Cited by 38
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells
Gerst, F., Kemter, E., Lorza‐Gil, E., Kaiser, G., Fritz, A.-K., Nano, R., Piemonti, L., Gauder, M., Dahl, A., Nadalin, S., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05435-1 · Cited by 35
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 35
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
Betteridge, D. J. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00741.x · Cited by 31
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome
Sunayama, S., Watanabe, Y., Daida, H., & Yamaguchi, H. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200008000-00009 · Cited by 31
Renal Artery Stenosis: New Findings from the CORAL Trial
Gupta, R., Assiri, S., & Cooper, C. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0894-2 · Cited by 29
Adamska, A., Polak, A. M., Krentowska, A., Łebkowska, A., Hryniewicka, J., Leśniewska, M., & Kowalska, I. (2019) · Endocrine Connections · doi:10.1530/ec-19-0243 · Cited by 26
Role of serum adropin measurement in the assessment of insulin resistance in obesity
Erman, H., Özdemir, A., Sitar, M. E., Cetin, S. I., & Böyük, B. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001796 · Cited by 26
Liver Fetuin-A at Initiation of Insulin Resistance
Lanthier, N., Lebrun, V., Molendi‐Coste, O., van Rooijen, N., & Leclercq, I. A. (2022) · Metabolites · doi:10.3390/metabo12111023 · Cited by 26
Using Mendelian randomization to determine causative factors in cardiovascular disease
Johansen, C. T., & Hegele, R. A. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02586.x · Cited by 24
Recent Developments in Delivery of MicroRNAs Utilizing Nanosystems for Metabolic Syndrome Therapy
Li, T., Zhu, L., Zhu, L., Wang, P., Xu, W., & Huang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157855 · Cited by 24
MicroRNAs in the pathogenesis of type 2 diabetes: new research progress and future direction
Miao, C., Zhang, G., Xie, Z., & Chang, J. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0452 · Cited by 23
Fetuin‐A excess expression amplifies lipid induced apoptosis and β‐cell damage
Mukhuty, A., Fouzder, C., & Kundu, R. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30499 · Cited by 23
Sadler, C. J., & Wilding, J. P. H. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.007 · Cited by 21
Cheng, Z.-B., Huang, L., Xiao, X., Sun, J.-X., Zou, Z.-K., Jiang, J.-F., Lu, C., Zhang, H.-Y., & Zhang, C. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.08.022 · Cited by 21
Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones
Prato, S. D., & Marchetti, P. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.719 · Cited by 19
Fatima, F., Ahsan, N., Nasim, A., & Alam, F. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.36.2.1106 · Cited by 19
Scheen, A. J. (2006) · RMLG. Revue médicale de Liège · Cited by 18
Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Brame, L. A., Verma, S., Anderson, T. J., Lteif, A. A., & Mather, K. J. (2004) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1568006043481275 · Cited by 15
Lee-Ødegård, S., Ueland, T., Thorsby, P. M., Aukrust, P., Michelsen, A. E., Halvorsen, B. L., Drevon, C. A., & Birkeland, K. I. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01127-y · Cited by 14
SNAITH, J. R., Samocha‐Bonet, D., Evans, J., Liu, Z., Kowalski, G. M., Bruce, C. R., Holmes-Walker, D. J., & Greenfield, J. R. (2021) · Diabetic Medicine · doi:10.1111/dme.14564 · Cited by 13
Wang, D., Wu, M., Zhang, X., Li, L., Lin, M., Shi, X., Zhao, Y., Huang, C., & Li, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-17000-w · Cited by 13
Hepatokines Fetuin-A and Fetuin-B status in obese Saudi patient with diabetes mellitus type 2.
Almarashda, O., Abdi, S., Yakout, S. M., Khattak, M. N. K., & Al‐Daghri, N. M. (2022) · PubMed · Cited by 11
Xia, X., Xue, S., Yang, G., Yu, L. J., Liu, H., Chen, C., & Li, L. (2021) · PeerJ · doi:10.7717/peerj.11869 · Cited by 10
Wakeel, M. E. S. E., Ahmad, I. H., Mohammed, M. A., Ali, S. M. O., Wahab, M. K. A. E., & Shipl, W. M. (2022) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_675_20 · Cited by 8
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
Scheen, A. J. (2007) · PubMed · Cited by 7
Li, Z., Liu, C., Shi, X., Chen, Z., Wang, D., Li, L., Tu, Y., Lin, M., Liu, S., Yang, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000009234 · Cited by 7
The insulin centennial—100 years of milestones in biochemistry
Attie, A., Tang, Q.-Q., & Bornfeldt, K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101278 · Cited by 6
Metadata
- Authors
- Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E.
- Venue
- Journal of International Medical Research
- Publisher
- SAGE Publications
- Published
- 2023-03
- Volume
- 51
- Issue
- 3
- Pages
- 3000605231164548-3000605231164548
- ISSN
- 0300-0605 (ISSN-L)
- 1473-2300
- OpenAlex
- W4361273400
- Cited by
- 385
- References
- 268
- FWCI
- 63.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.